Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$54.17
-1.6%		$56.36
$13.66
▼
$72.36
$1.61B0.71692,401 shs72,124 shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$7.33
+1.0%		$9.61
$6.32
▼
$20.56
$137.04M2.63447,924 shs349,296 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$11.71
-0.1%		$11.20
$7.36
▼
$13.90
$1.04B0.441.66 million shs380,086 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$43.23
-1.6%		$43.70
$15.86
▼
$50.81
$2.11B1.57801,680 shs154,006 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+1.38%-0.18%-6.66%-4.26%+177.94%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
0.00%-11.89%-27.98%-12.11%-37.52%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+4.64%+1.30%-4.95%+18.03%+44.87%
Urogen Pharma stock logo
URGN
Urogen Pharma
+1.06%+4.05%-10.16%+30.92%+142.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$54.17
-1.6%		$56.36
$13.66
▼
$72.36
$1.61B0.71692,401 shs72,124 shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$7.33
+1.0%		$9.61
$6.32
▼
$20.56
$137.04M2.63447,924 shs349,296 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$11.71
-0.1%		$11.20
$7.36
▼
$13.90
$1.04B0.441.66 million shs380,086 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$43.23
-1.6%		$43.70
$15.86
▼
$50.81
$2.11B1.57801,680 shs154,006 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+1.38%-0.18%-6.66%-4.26%+177.94%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
0.00%-11.89%-27.98%-12.11%-37.52%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+4.64%+1.30%-4.95%+18.03%+44.87%
Urogen Pharma stock logo
URGN
Urogen Pharma
+1.06%+4.05%-10.16%+30.92%+142.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.67
Moderate Buy$79.8546.41% Upside
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2.60
Moderate Buy$41.00460.03% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.75
Moderate Buy$25.40115.16% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
2.70
Moderate Buy$52.3819.33% Upside

Current Analyst Ratings Breakdown

Latest KURA, URGN, CRBP, and ANAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
9/10/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$56.00
8/31/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$78.00
8/26/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$75.00 ➝ $70.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold$70.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$24.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$24.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/24/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
8/24/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$24.00
(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M6.88N/AN/A$1.34 per share40.70
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$8.40 per shareN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M15.56N/AN/A$2.00 per share5.90
Urogen Pharma stock logo
URGN
Urogen Pharma
$109.79M19.54N/AN/A($2.25) per share-19.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M-$1.08N/A22.35N/A-11.53%N/A-7.75%9/23/2026 (Estimated)
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$78.54M-$6.19N/AN/AN/AN/A-87.05%-74.22%11/11/2026 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)
Urogen Pharma stock logo
URGN
Urogen Pharma
-$153.49M-$1.98N/A12.58N/A-51.73%N/A-43.79%11/5/2026 (Estimated)

Latest KURA, URGN, CRBP, and ANAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/23/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650N/AN/AN/A$14.06 millionN/A
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/6/2026Q2 2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.26-$1.81-$0.55-$1.81N/AN/A
8/5/2026Q2 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.2650-$0.28-$0.0150-$0.28$63.55 million$72.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
5.71
5.71
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
3.80
3.41

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.50%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.61 million20.28 millionOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3618.67 million18.02 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26088.96 million82.20 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
29148.88 million46.54 millionOptionable

Recent News About These Companies

Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
September 17 at 2:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31028170
Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from Analysts
September 17 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-urogen-pharma-nasdaq-urgn-receives-average-recommendation-of-moderate-buy-from-analysts-2026-09-17/
Urogen Pharma $URGN Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-urogen-pharma-urgn-shares-sold-by-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-2026-09-14/
Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock
September 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-urgn-insider-buying-and-selling-2026-09-10/
Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-urogen-pharma-nasdaq-urgn-insider-sells-3738332-in-stock-2026-09-09/
Jason Drew Smith Sells 1,519 Shares of Urogen Pharma (NASDAQ:URGN) Stock
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-jason-drew-smith-sells-1519-shares-of-urogen-pharma-nasdaq-urgn-stock-2026-09-09/
Urogen Pharma (NASDAQ:URGN) Trading Up 5.9% - Here's What Happened
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-urogen-pharma-nasdaq-urgn-trading-up-59-heres-what-happened-2026-09-09/
Urogen Pharma: Upside After Bladder Cancer Launch
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944329-urogen-pharma-upside-after-bladder-cancer-launch
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986284/take-the-zacks-approach-to-beat-the-markets-oportun-financial-uranium-royalty-amgen-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2986284
Legal & General Group Plc Invests $1.32 Million in Urogen Pharma $URGN
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-132-million-in-urogen-pharma-urgn-2026-09-07/
Bank of New York Mellon Corp Buys New Position in Urogen Pharma $URGN
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-buys-new-position-in-urogen-pharma-urgn-2026-09-06/
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356517/0/en/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
UroGen Pharma to Present at Upcoming Investor Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355097/0/en/urogen-pharma-to-present-at-upcoming-investor-conferences.html
BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-purchases-shares-of-3201461-urogen-pharma-urgn-2026-08-30/
Deutsche Bank AG Takes $1.90 Million Position in Urogen Pharma $URGN
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-takes-190-million-position-in-urogen-pharma-urgn-2026-08-29/
Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-palo-alto-investors-lp-purchases-new-shares-in-urogen-pharma-urgn-2026-08-28/
Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-buys-new-position-in-urogen-pharma-urgn-2026-08-28/
Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-coastal-bridge-advisors-llc-invests-136-million-in-urogen-pharma-urgn-2026-08-28/
Elmind Capital LP Invests $4.42 Billion in Urogen Pharma $URGN
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-elmind-capital-lp-invests-442-billion-in-urogen-pharma-urgn-2026-08-26/
ADAR1 Capital Management LLC Buys New Position in Urogen Pharma $URGN
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-buys-new-position-in-urogen-pharma-urgn-2026-08-26/
Parkman Healthcare Partners LLC Acquires New Position in Urogen Pharma $URGN
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-parkman-healthcare-partners-llc-acquires-new-position-in-urogen-pharma-urgn-2026-08-25/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$54.17 -0.89 (-1.62%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$7.33 +0.07 (+0.96%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$11.71 -0.01 (-0.09%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$43.22 -0.73 (-1.65%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas